Ann E. Berman - 21 Jun 2022 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 21 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2022, 17:08:37 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 06 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Ann E. Berman

Key filing fact

Ann E. Berman filed Form 4 for Immuneering Corp (IMRX) on 23 Jun 2022.

Key facts

This page summarizes Ann E. Berman's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2022, 17:08.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMRX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +14,200
Change %
Price: $0.000000
Shares after: 14,200
Date: 21 Jun 2022
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 14,200
Exercise price: $4.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever is earlier.